COVID-19は認知と記憶に小さいながらも持続的な影響を及ぼす可能性(COVID-19 may have small but lasting effects on cognition and memory)


2024-02-28 インペリアル・カレッジ・ロンドン(ICL)

イギリスのインペリアル・カレッジ・ロンドンの研究者による新しい研究では、COVID-19から回復した人々の認知および記憶タスクのパフォーマンスにわずかな欠損が見られ、COVID-19を患っていない人々と比較しています。この研究は、長期間の症状(つまり、ロングコビッド)が最終的に解消された人々も含まれます。また、入院が必要だった人や長期の症状が続いている人、または以前のウイルスの変異株に感染していた人々の場合、認知欠損はより大きかったことが示されています。この研究は、『New England Journal of Medicine』に発表されました。


大規模コミュニティサンプルにおけるCOVID-19後の認知と記憶 Cognition and Memory after Covid-19 in a Large Community Sample

Adam Hampshire, Ph.D.,Adriana Azor, Ph.D.,Christina Atchison, Ph.D.,William Trender, M.Res.,Peter J. Hellyer, Ph.D.,Valentina Giunchiglia, M.Sc.,Masud Husain, Ph.D.,Graham S. Cooke, Ph.D.,Emily Cooper, M.A.,Adam Lound, M.Sc.,Christl A. Donnelly, Ph.D.,Marc Chadeau-Hyam, Ph.D.,et al.
New England Journal of Medicine  Published:February 29, 2024
DOI: 10.1056/NEJMoa2311330


Cognitive symptoms after coronavirus disease 2019 (Covid-19), the disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), are well-recognized. Whether objectively measurable cognitive deficits exist and how long they persist are unclear.

We invited 800,000 adults in a study in England to complete an online assessment of cognitive function. We estimated a global cognitive score across eight tasks. We hypothesized that participants with persistent symptoms (lasting ≥12 weeks) after infection onset would have objectively measurable global cognitive deficits and that impairments in executive functioning and memory would be observed in such participants, especially in those who reported recent poor memory or difficulty thinking or concentrating (“brain fog”).

Of the 141,583 participants who started the online cognitive assessment, 112,964 completed it. In a multiple regression analysis, participants who had recovered from Covid-19 in whom symptoms had resolved in less than 4 weeks or at least 12 weeks had similar small deficits in global cognition as compared with those in the no–Covid-19 group, who had not been infected with SARS-CoV-2 or had unconfirmed infection (-0.23 SD [95% confidence interval {CI}, -0.33 to -0.13] and -0.24 SD [95% CI, -0.36 to -0.12], respectively); larger deficits as compared with the no–Covid-19 group were seen in participants with unresolved persistent symptoms (-0.42 SD; 95% CI, -0.53 to -0.31). Larger deficits were seen in participants who had SARS-CoV-2 infection during periods in which the original virus or the B.1.1.7 variant was predominant than in those infected with later variants (e.g., -0.17 SD for the B.1.1.7 variant vs. the B.1.1.529 variant; 95% CI, -0.20 to -0.13) and in participants who had been hospitalized than in those who had not been hospitalized (e.g., intensive care unit admission, -0.35 SD; 95% CI, -0.49 to -0.20). Results of the analyses were similar to those of propensity-score–matching analyses. In a comparison of the group that had unresolved persistent symptoms with the no–Covid-19 group, memory, reasoning, and executive function tasks were associated with the largest deficits (-0.33 to -0.20 SD); these tasks correlated weakly with recent symptoms, including poor memory and brain fog. No adverse events were reported.

Participants with resolved persistent symptoms after Covid-19 had objectively measured cognitive function similar to that in participants with shorter-duration symptoms, although short-duration Covid-19 was still associated with small cognitive deficits after recovery. Longer-term persistence of cognitive deficits and any clinical implications remain uncertain. (Funded by the National Institute for Health and Care Research and others.)